The accumulation of amyloid beta and tau are regarded as one of the earliest
signs and the pathological hallmarks of Alzheimer's disease (AD).2 Accumulation of both amyloid and tau starts 15 years prior to symptom onset.3
These biomarkers reflect the specific pathological accumulation of amyloid beta in plaques and tau in neurofibrillary tangles in the brain, serving as detectable signs of AD pathogenesis.2
Biomarkers enhance diagnostic accuracy and physician confidence in early diagnosis.4
A positive pTau181/Abeta42 ratio result in CSF does not establish a diagnosis of Alzheimer's disease (AD) and should always be interpreted in conjunction with clinical information.